: Enhancing Radiation Safety for Nuclear Medicine Radiographers: the Impact of Introducing the Automat-ed Radiopharmaceutical Preparation and Administration System
Conditions: Radiation Exposure Interventions: Radiation: automated system in reducing radiation exposure Sponsors: IRCCS San Raffaele Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Conditions: Cancer Sponsors: Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Study of the in Vivo Expression of MU Opioid Receptors Using PET and the Selective Tracer [C-11] Carfentanil in Normal Weight and Obese Subjects
Conditions: Nuclear Medicine Interventions: Diagnostic Test: PET for the analysis of mu opioid receptor expression. Sponsors: IRCCS San Raffaele Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine
Conditions: Cancer; Myocarditis; Alzheimer Disease; Parkinson Interventions: Other: Ericksonian Hypnosis; Other: Hypnosis Sponsors: Central Hospital, Nancy, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
NUclear MEdicine DIagnostic and Artificial Intelligence
Condition: Hyperparathyroidism Intervention: Device: treatment program Sponsors: Centre Hospitalier Universitaire de Besancon; Franche-Comté Electronique Mécanique Thermique et Optique - Sciences et Technologies, UMR 6174 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials
PRospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With ChemoradIotherapy Followed by cONsolidation Therapy With Durvalumab (PRECISION)
Conditions: Oncology; Biomarker; NSCLC, Stage III; Durvalumab; Chemoradiotherapy Intervention: Other: Non-interventional Sponsors: LMU Klinikum; Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany; Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; Asklepios Lung Clinic, Munich-Gauting, Germany; Department of Radiology, University Hospital, LMU Munich, Munich, Germany; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Institute for Medical Information Processing, Biometry and Epi...
Source: ClinicalTrials.gov - August 30, 2021 Category: Research Source Type: clinical trials
